ProofPilot, a startup that helps researchers design and manage scientific studies, launches today after a $1.85 million investment from CueBall Capital and Brooklyn Bridge Ventures, among others.
The New York-based startup says it makes it easier for professionals to run randomized controlled trials and outcome studies by reducing systematic issues that might come up while conducting them.
“I became increasingly frustrated that insightful health and social innovations were getting lost because it was too expensive to test whether [HIV prevention studies] really worked,” said cofounder Matthew Amsden. “I knew there had to be a more efficient way to do research studies.”
The company raised the capital in 2014, then “had to go on a brief break,” Amsden said, to further develop its technology. Now, ProofPilot is back, aiming to allow “researchers’ work to be guided by curiosity, not by concerns about protocol.”
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more